TR199801749T2 - 4-Amino-pyrimidine-derivatives and drugs containing them - Google Patents

4-Amino-pyrimidine-derivatives and drugs containing them

Info

Publication number
TR199801749T2
TR199801749T2 TR1998/01749T TR9801749T TR199801749T2 TR 199801749 T2 TR199801749 T2 TR 199801749T2 TR 1998/01749 T TR1998/01749 T TR 1998/01749T TR 9801749 T TR9801749 T TR 9801749T TR 199801749 T2 TR199801749 T2 TR 199801749T2
Authority
TR
Turkey
Prior art keywords
pyrimidine
derivatives
amino
drugs containing
treatment
Prior art date
Application number
TR1998/01749T
Other languages
Turkish (tr)
Inventor
Himmelsbach Frank
Dahmann Georg
von R�den Thomas
Metz Thomas
Original Assignee
Dr. Karl Thomae Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996108631 external-priority patent/DE19608631A1/en
Application filed by Dr. Karl Thomae Gmbh filed Critical Dr. Karl Thomae Gmbh
Publication of TR199801749T2 publication Critical patent/TR199801749T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Yukaridaki bulus, içinde Ra,Rb, A ve B'nin istem 1'de tanimlandigi gibi oldugu genel formül (I)'in 4-amino-pirimidin-türevleri, bunlarin tautomerleri, stereoizomerleri ve tuzlari, özellikle farmakolojik olarak degerli özelliklerde titrosinkinazlar ile bildirilen sinyal transdüksiyonun önleme etkisi özelliklerine sahip olan anorganik ya da organik asit ya da bazlar ile birlikte bunlarin fizyolojik olarak uygun tuzlari, bunlarin hastaliklarin özelliklede tümör hastaliklarinin tedavisi için kullanimi ve bunlanir elde edilmesi ile ilgilidir. FORMÜL.The above invention is reported by the 4-amino-pyrimidine-derivatives of the general formula (I) in which Ra, Rb, A, and B are as defined in claim 1, their tautomers, stereoisomers and salts, in particular pharmacologically valuable titrosynkinases. Inorganic or organic acids or bases, together with their signal transduction inhibitory properties, are concerned with their physiologically acceptable salts, their use for the treatment of diseases, and particularly their treatment of tumor diseases. FORMULA.

TR1998/01749T 1996-03-06 1997-03-03 4-Amino-pyrimidine-derivatives and drugs containing them TR199801749T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996108631 DE19608631A1 (en) 1996-03-06 1996-03-06 New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives
DE19629652A DE19629652A1 (en) 1996-03-06 1996-07-23 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation

Publications (1)

Publication Number Publication Date
TR199801749T2 true TR199801749T2 (en) 1998-12-21

Family

ID=26023531

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01749T TR199801749T2 (en) 1996-03-06 1997-03-03 4-Amino-pyrimidine-derivatives and drugs containing them

Country Status (19)

Country Link
EP (1) EP0885226A1 (en)
JP (1) JP2000506847A (en)
KR (1) KR19990087550A (en)
CN (1) CN1212695A (en)
AU (1) AU710274B2 (en)
BG (1) BG102708A (en)
BR (1) BR9708312A (en)
CA (1) CA2243994A1 (en)
CZ (1) CZ281798A3 (en)
DE (1) DE19629652A1 (en)
EE (1) EE9800277A (en)
HU (1) HUP9901820A3 (en)
IL (1) IL125404A0 (en)
NO (1) NO984084L (en)
NZ (1) NZ331546A (en)
PL (1) PL328771A1 (en)
SK (1) SK120598A3 (en)
TR (1) TR199801749T2 (en)
WO (1) WO1997032881A1 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801530T2 (en) 1996-02-13 1998-11-23 Zeneca Limited Quinazoline derivatives as VEGF inhibitors.
PT885198E (en) 1996-03-05 2002-06-28 Astrazeneca Ab 4-ANYLINOQUINAZOLINE DERIVATIVES
EP1396489A1 (en) * 1999-01-27 2004-03-10 Pfizer Products Inc. Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
UA72946C2 (en) 1999-11-05 2005-05-16 Астразенека Аб Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf)
BRPI0411608A (en) 2003-06-24 2006-08-08 Neurosearch As 8-aza-bicyclo [3.2.1] octane derivative, pharmaceutical composition, use of the compound, and method of treating, preventing or alleviating a disease, disorder or condition of a living animal organism
MX2007010068A (en) * 2005-02-16 2007-10-10 Schering Corp Piperazine-piperidines with cxcr3 antagonist activity.
EP2349235A1 (en) 2008-11-07 2011-08-03 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
CA2745041C (en) * 2008-12-01 2017-08-22 Kai Schiemann 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
JP2013510564A (en) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CA2845179A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
JP2014531213A (en) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド Diagnostic methylation markers for epithelial or mesenchymal phenotype and response to EGFR kinase inhibitors in tumors or tumor cells
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
EP2961412A4 (en) 2013-02-26 2016-11-09 Triact Therapeutics Inc Cancer therapy
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
AU2015371312B2 (en) 2014-12-24 2022-01-27 Genentech, Inc. Therapeutic, diagnostic and prognostic methods for cancer of the bladder
ES2894255T3 (en) 2016-12-22 2022-02-14 Amgen Inc Benzoisothiazole derivatives, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors to treat lung cancer pancreatic or colorectal
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
UY37870A (en) 2017-09-08 2019-03-29 Amgen Inc KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
AU2019265822A1 (en) 2018-05-10 2020-11-19 Amgen Inc. KRAS G12C inhibitors for the treatment of cancer
MA52765A (en) 2018-06-01 2021-04-14 Amgen Inc KRAS G12C INHIBITORS AND THEIR PROCEDURES FOR USE
MA52780A (en) 2018-06-11 2021-04-14 Amgen Inc KRAS G12C INHIBITORS FOR CANCER TREATMENT
AU2019336588B2 (en) 2018-06-12 2022-07-28 Amgen Inc. KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CA3115038A1 (en) 2018-10-04 2020-04-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Egfr inhibitors for treating keratodermas
JP2020090482A (en) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Improved synthesis of key intermediate of kras g12c inhibitor compound
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
MX2021005700A (en) 2018-11-19 2021-07-07 Amgen Inc Kras g12c inhibitors and methods of using the same.
MX2021007156A (en) 2018-12-20 2021-08-16 Amgen Inc Kif18a inhibitors.
MX2021007158A (en) 2018-12-20 2021-08-16 Amgen Inc Heteroaryl amides useful as kif18a inhibitors.
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
EP3897855B1 (en) 2018-12-20 2023-06-07 Amgen Inc. Kif18a inhibitors
SG11202109036WA (en) 2019-03-01 2021-09-29 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CN114144414A (en) 2019-05-21 2022-03-04 美国安进公司 Solid state form
MX2022001295A (en) 2019-08-02 2022-02-22 Amgen Inc Kif18a inhibitors.
MX2022001296A (en) 2019-08-02 2022-02-22 Amgen Inc Kif18a inhibitors.
EP4007638A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Pyridine derivatives as kif18a inhibitors
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CR20220240A (en) 2019-11-04 2022-08-03 Revolution Medicines Inc Ras inhibitors
TW202132314A (en) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras inhibitors
JP2022553858A (en) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド RAS inhibitor
CA3156359A1 (en) 2019-11-08 2021-05-14 Adrian Liam Gill Bicyclic heteroaryl compounds and uses thereof
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
US20230192681A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
TW202140011A (en) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2 inhibitor dosing and methods of treating cancer
KR20230042600A (en) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Methods of Delaying, Preventing, and Treating Acquired Resistance to RAS Inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as ras inhibitors in the treatment of cancer
JP2024501280A (en) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド SOS1 inhibitors and their uses
CR20230570A (en) 2021-05-05 2024-01-22 Revolution Medicines Inc Ras inhibitors
AR125787A1 (en) 2021-05-05 2023-08-16 Revolution Medicines Inc RAS INHIBITORS
CN117500811A (en) 2021-05-05 2024-02-02 锐新医药公司 Covalent RAS inhibitors and uses thereof
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
TW202340214A (en) 2021-12-17 2023-10-16 美商健臻公司 Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE4431867A1 (en) * 1994-09-07 1996-03-14 Thomae Gmbh Dr K New 4-amino-pyrimido-pyrimidine derivs.

Also Published As

Publication number Publication date
HUP9901820A2 (en) 1999-09-28
CN1212695A (en) 1999-03-31
NO984084D0 (en) 1998-09-04
DE19629652A1 (en) 1998-01-29
AU1925197A (en) 1997-09-22
BG102708A (en) 1999-09-30
AU710274B2 (en) 1999-09-16
CA2243994A1 (en) 1997-09-12
SK120598A3 (en) 1999-06-11
EP0885226A1 (en) 1998-12-23
EE9800277A (en) 1999-02-15
JP2000506847A (en) 2000-06-06
CZ281798A3 (en) 1999-02-17
BR9708312A (en) 1999-08-03
NO984084L (en) 1998-09-04
PL328771A1 (en) 1999-02-15
KR19990087550A (en) 1999-12-27
NZ331546A (en) 2000-03-27
HUP9901820A3 (en) 2001-10-29
IL125404A0 (en) 1999-03-12
WO1997032881A1 (en) 1997-09-12

Similar Documents

Publication Publication Date Title
TR199801749T2 (en) 4-Amino-pyrimidine-derivatives and drugs containing them
TR200102505T2 (en) 4-amino-quinazoline and quinoline derivatives.
TR199801753T2 (en) Drugs containing pyrimido(5,4-D) pyrimidine compound, their use and production processes.
TR200201505T2 (en) Pirazolopyrimidines as therapeutic agents
CA2199401A1 (en) Pyrimido[5,4-d]pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
MY123642A (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them.
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
CA2375259A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BR0014178A (en) Dicarboxylic acid derivatives with pharmaceutical properties
ATE264846T1 (en) SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR TREATING RETROVIRAL INFECTIONS
CA2216796A1 (en) Quinazoline derivatives
TR200201168T2 (en) CGRP-Antagonists-drugs containing new cyclopropanes and production methods.
MX9803954A (en) Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them.
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
ATE233274T1 (en) OXYIMINOPREGNANCARBOLACTONE
AP9701041A0 (en) Pyridylpyrrole compounds.
TR200103460T2 (en) 5-Phenyl-pyrimidine derivatives
TR199801840A2 (en) New imidazolidine derivatives and pharmacological preparations containing them.
NO951484D0 (en) Quinolone and acridinone derivatives for the treatment of urinary incontinence
CO4410330A1 (en) NEW DERIVATIVES OF PHARMACOLOGICALLY ACTIVE BENZMIDAZOLE AND ITS ADDITIONAL SALTS
WO2000055162A3 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
TR200103457T2 (en) 4-Phenyl-Pyrimidine Derivatives.
ES2178301T3 (en) DERIVATIVES OF PENICILANIC ACID 2-BETA-SUBSTITUTED-6-RENTED AS INHIBITORS OF BETA-LACTAMA.
TR199701202T1 (en) New hydroxymic acid derivatives.
TR200200017T2 (en) Benzofuran derivatives